BioSpace News Archive

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, issued the following statement in response to the release from Richard Kayne:

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces that Joshua Schafer has been appointed as interim Chairman of the Pharnext Board of Directors with immediate effect.

Halia Therapeutics, a biotechnology company that has used a structure-based drug design strategy to discover a series of small molecule therapeutics targeting essential mediators of inflammation, presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Akebia’s New Drug Application (NDA) for vadadustat.

A study published in the Journal of the American Medical Association Surgery is the first in North America to demonstrate that living-donor liver transplant is a viable option for patients who have systemically controlled colorectal cancer and liver tumors that cannot be surgically removed.

Concentric Analgesics, Inc. today announced positive results from its recently completed pilot Phase 2 clinical trial of vocacapsaicin in patients undergoing open laparotomy for ventral hernia repair.

Alpine Immune Sciences, Inc. today announced that Alpine will host a virtual investor event on April 12th , 2022 at 6:00pm ET.

CytoDyn Inc. announced that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, has been invited to present at the 21st Annual Needham Virtual Healthcare Conference taking place from April 11 – 14.

NAMSA announced today its nearing acquisition of Medanex Clinic , a Belgium-based European preclinical research organization.